Cargando…

Molecularly Imprinted Carriers for Diagnostics and Therapy—A Critical Appraisal

Simultaneous diagnostics and targeted therapy provide a theranostic approach, an instrument of personalized medicine—one of the most-promising trends in current medicine. Except for the appropriate drug used during the treatment, a strong focus is put on the development of effective drug carriers. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Balcer, Emilia, Sobiech, Monika, Luliński, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304065/
https://www.ncbi.nlm.nih.gov/pubmed/37376096
http://dx.doi.org/10.3390/pharmaceutics15061647
_version_ 1785065420247531520
author Balcer, Emilia
Sobiech, Monika
Luliński, Piotr
author_facet Balcer, Emilia
Sobiech, Monika
Luliński, Piotr
author_sort Balcer, Emilia
collection PubMed
description Simultaneous diagnostics and targeted therapy provide a theranostic approach, an instrument of personalized medicine—one of the most-promising trends in current medicine. Except for the appropriate drug used during the treatment, a strong focus is put on the development of effective drug carriers. Among the various materials applied in the production of drug carriers, molecularly imprinted polymers (MIPs) are one of the candidates with great potential for use in theranostics. MIP properties such as chemical and thermal stability, together with capability to integrate with other materials are important in the case of diagnostics and therapy. Moreover, the MIP specificity, which is important for targeted drug delivery and bioimaging of particular cells, is a result of the preparation process, conducted in the presence of the template molecule, which often is the same as the target compound. This review focused on the application of MIPs in theranostics. As a an introduction, the current trends in theranostics are described prior to the characterization of the concept of molecular imprinting technology. Next, a detailed discussion of the construction strategies of MIPs for diagnostics and therapy according to targeting and theranostic approaches is provided. Finally, frontiers and future prospects are presented, stating the direction for further development of this class of materials.
format Online
Article
Text
id pubmed-10304065
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103040652023-06-29 Molecularly Imprinted Carriers for Diagnostics and Therapy—A Critical Appraisal Balcer, Emilia Sobiech, Monika Luliński, Piotr Pharmaceutics Review Simultaneous diagnostics and targeted therapy provide a theranostic approach, an instrument of personalized medicine—one of the most-promising trends in current medicine. Except for the appropriate drug used during the treatment, a strong focus is put on the development of effective drug carriers. Among the various materials applied in the production of drug carriers, molecularly imprinted polymers (MIPs) are one of the candidates with great potential for use in theranostics. MIP properties such as chemical and thermal stability, together with capability to integrate with other materials are important in the case of diagnostics and therapy. Moreover, the MIP specificity, which is important for targeted drug delivery and bioimaging of particular cells, is a result of the preparation process, conducted in the presence of the template molecule, which often is the same as the target compound. This review focused on the application of MIPs in theranostics. As a an introduction, the current trends in theranostics are described prior to the characterization of the concept of molecular imprinting technology. Next, a detailed discussion of the construction strategies of MIPs for diagnostics and therapy according to targeting and theranostic approaches is provided. Finally, frontiers and future prospects are presented, stating the direction for further development of this class of materials. MDPI 2023-06-03 /pmc/articles/PMC10304065/ /pubmed/37376096 http://dx.doi.org/10.3390/pharmaceutics15061647 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Balcer, Emilia
Sobiech, Monika
Luliński, Piotr
Molecularly Imprinted Carriers for Diagnostics and Therapy—A Critical Appraisal
title Molecularly Imprinted Carriers for Diagnostics and Therapy—A Critical Appraisal
title_full Molecularly Imprinted Carriers for Diagnostics and Therapy—A Critical Appraisal
title_fullStr Molecularly Imprinted Carriers for Diagnostics and Therapy—A Critical Appraisal
title_full_unstemmed Molecularly Imprinted Carriers for Diagnostics and Therapy—A Critical Appraisal
title_short Molecularly Imprinted Carriers for Diagnostics and Therapy—A Critical Appraisal
title_sort molecularly imprinted carriers for diagnostics and therapy—a critical appraisal
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304065/
https://www.ncbi.nlm.nih.gov/pubmed/37376096
http://dx.doi.org/10.3390/pharmaceutics15061647
work_keys_str_mv AT balceremilia molecularlyimprintedcarriersfordiagnosticsandtherapyacriticalappraisal
AT sobiechmonika molecularlyimprintedcarriersfordiagnosticsandtherapyacriticalappraisal
AT lulinskipiotr molecularlyimprintedcarriersfordiagnosticsandtherapyacriticalappraisal